Boehringer Ingelheim
-
FDA approves Humira biosimilar as first-ever interchangeable monoclonal antibody
Boehringer Ingelheim has shown biosimilar manufacturers the way to win interchangeability with the world’s highest-grossing drug — but the company’s Cyltezo won’t come out until July 2023. Will future Humira competitors have better luck winning an earlier launch date?
-
These drug patents are expected to expire in 2020
According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. Two reports list 18 drugs as losing patent protection or exclusivity, though not all drugs listed here will necessarily face generic or biosimilar competition in 2020.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Singapore biotech could get more than $1B from Boehringer Ingelheim under partnership
The German drugmaker announced a partnership with Enleofen to develop the company’s suite of preclinical antibodies targeting IL-11 in diseases like NASH.
-
Boehringer Ingelheim dumps NASH drug program amid concerns over drug interactions
BI said it would continue to develop the drug, BI 1467335, in other diseases and remain committed to NASH overall. Shares of the Australian company from which it licensed the drug, Pharmaxis, fell more than 40%.
-
Boehringer Ingelheim, MD Anderson to develop cancer drugs under research partnership
The two organizations are placing particular emphasis on lung and gastrointestinal cancers, as well as drug targets like KRAS mutations.
-
Boehringer Ingelheim to acquire Swiss cancer vaccine developer for up to 325M euros
The deal includes an upfront payment and up to 100 million euros in milestones, equaling $364.5 million. Amal’s lead candidate is a vaccine for colorectal cancer expected to enter the clinic later this month.
-
It’s not about what blockchain can do in healthcare, but what it’s already doing
A panel discussion at the upcoming MedCity INVEST meeting in Chicago will look at real-world applications of blockchain technology in healthcare and biopharma.
-
Boehringer Ingelheim, IBM to study blockchain in clinical trials
At the ongoing HIMSS conference in Orlando, Florida, the companies’ Canadian divisions said their partnership would mark the technology’s first use in clinical trials in Canada.
-
Biosimilars market set to nearly quadruple in next five years, report finds
Market forecast rosy, though market in United States remains young.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Qualcomm Life, Philips team up on connected health
Qualcomm Life also announced Tuesday that it would work with Boehringer Ingelheim Pharmaceuticals to develop a disposable, wireless connectivity module for the drug company’s Respimat inhaler.
-
Centrexion nabs three non-opioid pain drugs from Boehringer Ingelheim
Boehringer Ingelheim offloaded the drugs, it said in a statement. because it’s shifting away from pain medications to focus on CNS diseases like Alzheimer’s, schizophrenia and depression.
-
Boehringer Ingelheim backs commercialization of connected inhalers for COPD, asthma patients
Patients on Boehringer Ingelheim drugs for respiratory conditions have the option to enroll with certain health systems to get free access to inhalers embedded with Propeller Health sensors.
-
Morning Read: A Boehringer-Sanofi swap, one solid suggestion for Theranos
Also, a new deal for Illumina, a cure for Martin Shkreli, a controversial hospital acquisition and another Obamacare deadline approaches.
-
In quest to understand patient experience, pharma companies turn to ethnographers (video)
Pharmaceutical companies are turning to ethnographers to get a better appreciation for the diversity of the patient experience.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
